Secondary hyperparathyroidism (HPT) in patients receiving peritoneal dialysis (PD) can be effectively managed with cinacalcet (MIMPARA®/SENSIPAR®)

被引：0
|
作者：
Gonzalez, M. T.
Hutchison, A. J.
Girndt, M.
Stahl-Nilsson, A.
Zani, V.
Carter, D.
Molemans, B.
Bos, W. J. W.
机构：
[1] Hosp Univ Bellvitge, Barcelona, Spain
[2] Mission Res Inc, Manchester, Lancs, England
[3] Univ Saarlandes Kliniken, Homburg, Germany
[4] Lanssjukhuset Ryhov, Jonkoping, Sweden
[5] Amgen Inc, Zug, Switzerland
[6] St Antonius Hosp, Nieuwegein, Netherlands
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2006年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
引用
收藏
页码：134 / 134
页数：1
相关论文
共 50 条
  • [21] Early response to cinacalcet in peritoneal dialysis patients with tertiary hyperparathyroidism
    Lindley, Elizabeth
    Rahman, Nageena
    Woodrow, Graham
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 359 - 359
  • [22] Effect of cinacalcet treatment on vascular arterial stiffness among peritoneal dialysis patients with secondary hyperparathyroidism
    Chow, Kai Ming
    Szeto, Cheuk Chun
    Kwan, Bonnie Ching-Ha
    Cheng, Phyllis Mei-Shan
    Pang, Wing Fai
    Leung, Chi Bon
    Li, Philip Kam-Tao
    NEPHROLOGY, 2014, 19 (06) : 339 - 344
  • [23] Cinacalcet HCl controls secondary hyperparathyroidism (HPT) regardless of gender, race, age, and geography in patients with chronic kidney disease (CKD) receiving dialysis.
    Coyne, DW
    Stegman, MH
    Azad, H
    Joy, MS
    Mischel, SF
    Pokroy, N
    Ouseph, R
    Gokal, R
    Brink, HS
    Jadoul, M
    Olson, KA
    Albizem, MB
    Klassen, PS
    Chertow, GM
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 464A - 464A
  • [24] Cinacalcet for the treatment of secondary hyperparathyroidism (HPT) in patients non responsive to vitamin D
    Malberti, Fabio
    Villa, Giuseppe
    Colussi, Giacomo
    Mingardi, Giulio
    Quartagno, Rita
    Limido, Aurelio
    Conte, Ferruccio
    Farina, Marco
    Montagna, G.
    Vezzoli, Giuseppe
    Ravani, Pietro
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 129 - 129
  • [25] Use of Cinacalcet HCL (MIMPARA®/SENSIPAR®) to control mineral metabolism in patients with end-stage renal disease (ESRD) on dialysis complicated by secondary hyperparathyroidism (SHPT):: A cost-consequence analysis of Cinacalcet HCL versus standard of care (SC)
    Perrault, Louise
    Carter, Dave
    Molemans, Bart
    Maetzel, Andreas
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 136 - 136
  • [26] 1,25-dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar®/Mimpara®) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism
    Henley, C
    Colloton, M
    Cattley, RC
    Shatzen, E
    Towler, DA
    Lacey, D
    Martin, D
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (07) : 1370 - 1377
  • [27] Early use of cinacalcet (MIMPARA®/SENSIPAR®) in dialysis patients enables greatest achievement of NKF-KDOQI™ treatment targets for bone metabolism
    Frazao, J. M.
    Messa, P.
    Cunningham, J.
    Evenepoel, P.
    Shahapuni, I.
    Urena, P.
    Braun, J.
    Zani, V.
    Banos, A.
    Molemans, B.
    de Francisco, A. L. M.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 8 - 9
  • [28] Cinacalcet: A new treatment for secondary hyperparathyroidism in patients receiving hemodialysis
    Byrnes, CA
    Shepler, BM
    PHARMACOTHERAPY, 2005, 25 (05): : 709 - 716
  • [29] Cinacalcet Treatment in Dialysis Patients with Secondary Hyperparathyroidism: Effects and Open Issues
    Drueeke, Tilman B.
    THERAPEUTIC APHERESIS AND DIALYSIS, 2008, 12 : S2 - S12
  • [30] Calcimimetics for the treatment of secondary hyperparathyroidism in peritoneal dialysis patients
    Francis, Jean
    Simon, David B.
    Jeurgensen, Peter
    Finkelstein, Fredric O.
    PERITONEAL DIALYSIS INTERNATIONAL, 2008, 28 : S42 - S46
12345